Ekso Bionics Holdings, Inc. (OTCBB:EKSO) Hesitates After A Strong Boost

[[tagnumber 0]][[tagnumber 1]]Despite the many session in the red Ekso Bionics Holdings, Inc. (OTCBB:EKSO)’s stock has been doing quite well since the start of October, when it managed to move above the $1 per share mark and not only stay there, but go even further up the charts.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]The positive news about partnerships and business developments kept coming in and boosted investor confidence, while in the meantime, the company filed its financial report for the third quarter of the year, which boasted some impressive numbers. Here are the ones of prime interest.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 9]] [[tagnumber 10]]cash: $7.17 million[[tagnumber 11]] [[tagnumber 10]]current assets: $11.66 million[[tagnumber 11]] [[tagnumber 10]]total assets: $15.41 million[[tagnumber 11]] [[tagnumber 10]]current liabilities: $5.89 million[[tagnumber 11]] [[tagnumber 10]]total liabilities: $21.34 million[[tagnumber 11]] [[tagnumber 10]]quarterly revenues: $1.58 million[[tagnumber 11]] [[tagnumber 10]]loss from operations: $3.73 million[[tagnumber 11]] [[tagnumber 24]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Undoubtedly, these are not the numbers that you would see in your everyday OTC entity and despite the significant amount of liabilities it is obvious that the company is perfectly capable to carry on with its operations in the near future. Another positive sign is that [[tagnumber 28]]EKSO [[tagnumber 29]]is actually generating a healthy amount of revenues, despite being unable to do so at a profit.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]In the meantime it has embarked on projects in collaboration with [[tagnumber 28]]Ottobock [[tagnumber 29]]and it was chosen by Google, Inc. (NASDAQ:GOOG)’s Boston Dynamics as a partner in [[tagnumber 28]]DARPA’s [[tagnumber 29]]Warrior Web project, as well as receiving its first National Institute of Health (NIH) grant for the development of a pediatric exoskeleton.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Those news were what fueled the positive direction in which [[tagnumber 28]]EKSO [[tagnumber 29]]was headed throughout October and the beginning of November. More recently, the ticker has been on the slide, but a new press release managed to regain some of [[tagnumber 28]]EKSO’s [[tagnumber 29]]lost value.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]On November 24 the company announced that a total of 22.8 million of $2 warrants have been exercised at a reduced price of $1 per share, providing $22.8 million in gross proceeds, which will be used to expand the business.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]This led to a good 15.89% jump in value in Monday’s session, as the ticker closed at a price of $1.75. The amount of shares that were traded came to 901 thousand, which generated $1.41 million in daily dollar volume.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Still, the hype was short–lived and [[tagnumber 28]]EKSO [[tagnumber 29]]closed yesterday’s session in the red after it dropped 4% in price. This might be due to the realization that the 22.8 million shares will not only be issued at a discount of around 40% of the previous day’s closing price, but will increase the outstanding share count of EKSO by more than 25%.[[tagnumber 2]] [[tagnumber 0]] [[tagnumber 2]] [[tagnumber 0]]Furthermore, if the people who received the discounted shares decide to make a profit this might push the price down fast, so you should be sure to do your due diligence and weigh out the risks before putting any money on the line.[[tagnumber 2]]